Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 11/2001

Content (6 Articles)

ORIGINAL ARTICLE

Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes

Aline Van Pel, Etienne De Plaen, Marie-Thérèse Duffour, Guy Warnier, Catherine Uyttenhove, Michel Perricaudet, Thierry Boon

ORIGINAL ARTICLE

The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model

Douglas A. Arenberg, Albert Zlotnick, Scott R. B. Strom, Marie D. Burdick, Robert M. Strieter

ORIGINAL ARTICLE

Tumour-induced suppression of immune response and its correction

G.-A. Banat, O. Christ, B. Cochlovius, H. B. Pralle, M. Zöller

ORIGINAL ARTICLE

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient

L. M. Real, P. Jimenez, A. Kirkin, A. Serrano, A. García, J. Cantón, J. Zeuthen, F. Garrido, F. Ruiz-Cabello

ORIGINAL ARTICLE

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study

Jörg Westermann, Gernot Reich, Joachim Kopp, Ulrike Haus, Bernd Dörken, Antonio Pezzutto

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine